It's a wrap: GSK and Novartis megadeal completes
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Novartis have completed the landmark three-part transaction that they announced last April. GSK, which is affected more significantly than its larger European peer by the resulting changes, says it will hold an investor meeting on 6 May where it will provide 2015 earnings guidance and profile the medium and long-term shape of the company.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.
Need a specific report? 1000+ reports available
Buy Reports